Evidence map›Paper›PMID 40358154›Full record

ArticleCells2025

Combined Transplantation of Mesenchymal Progenitor and Neural Stem Cells to Repair Cervical Spinal Cord Injury.

Seok Voon White, Yee Hang Ethan Ma, Christine D Plant, Alan R Harvey, Giles W Plant

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Stem Cells in Aging and Anti-Aging.Stem cell reviews and reports · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seok Voon WhiteDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yee Hang Ethan MaDepartment of Neuroscience, The Ohio State University, Columbus, OH 43210, USA.ORCID 0009-0007-0537-8896
Christine D PlantDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alan R HarveySchool of Human Sciences, University of Western Australia, Crawley, WA 6009, Australia.
Giles W PlantDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-7366-652X

Funding

Stanford University SINTN
6 · The paper itself

Abstract

Mesenchymal progenitor cells (MPC) are effective in reducing tissue loss, preserving white matter, and improving forelimb function after a spinal cord injury (SCI). We proposed that by preconditioning the mouse by the intravenous delivery (IV) of MPCs for 24 h following SCI, this would provide a more favorable tissue milieu for an NSC intraspinal bridging transplantation at day three and day seven. In combination, these transplants will provide better anatomical and functional outcomes. The intravenous MSCs would provide cell protection and reduce inflammation. NSCs would provide a tissue bridge for axonal regeneration and myelination and reconnect long tract spinal pathways. Results showed that initial protection of the injury site by IV MPCs transplantation resulted in no increased survival of the NSCs transplanted at day seven. However, integration of transplanted NSCs was increased at the day three timepoint, indicating MPCs influence very early immune signaling. We show, in this study, that MPC transplantation resulted in a co-operative NSC cell survival improvement on day three post-SCI. In addition to increased NSC survival on day three, there was an increase in NSC-derived mature oligodendrocytes at this early timepoint. An in vitro analysis confirmed MPC-driven oligodendrocyte differentiation, which was statistically increased when compared to control NSC-only cultures. These observations provide important information about the combination, delivery, and timing of two cellular therapies in treating SCI. This study provides important new data on understanding the MPC inflammatory signaling within the host tissue and timepoints for cellular transplantation survival and oligodendroglia differentiation. These results demonstrate that MPC transplantation can alter the therapeutic window for intraspinal transplantation by controlling both the circulating inflammatory response and local tissue milieu.

Indexed as

Cervical CordMesenchymal Stem CellsMesenchymal Stem Cell TransplantationNeural Stem CellsSpinal Cord InjuriesAnimalsCell DifferentiationCell SurvivalFemaleMiceMice, Inbred C57BLOligodendrogliabridging/relay graftcervical spinal cord injurycombinatorial cellular transplantationintravenous transplantationmesenchymal progenitor cellsneural stem cells

Identifiers

PMID40358154
PMCPMC12072178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.